Tag Archives: Europe

Opening Up Innovation

Cancer

Open Innovation has become a major theme in the life sciences over the last couple of years. Most of the attention has focused on initiatives where big pharma offers access to non-core assets to outside researchers in the hope that they will develop them successfully or form collaborations. In Sweden, AstraZeneca have followed this path, but interest in the concept has spread further down the discovery chain, generating creative initiatives from universities, tech transfer organizations, Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Patent Utility Requirements for Biopharmaceutical Inventions: How Much is Enough?

Credit: Andrea Sivarsson

A debate between the innovative and generic perspectives on pharmaceutical patent law in Canada, moderated by David Kappos, will be held in Chicago on Monday April 22nd from 2:30-3:30pm in room S404A at this year’s BIO International Convention. Former Undersecretary of Commerce for Intellectual Property and USPTO Director David J. Kappos will moderate a panel of legal experts who will discuss recent developments in the area of patent utility and its implications for biopharmaceutical innovation.  Read More >

Patently BIOtech  |  1 Comment  |  Email This Post
Tags: , , , , , , ,

EU Stem Cell Patent Decision Hurts Science

Æ

A great article in the Economist titled European science stemmed addresses the recent and controversial decision by the European Court of Justice regarding the patentability of certain inventions derived from embryonic stem cells. ANY country, you might think, would relish being able to call itself the world’s leader in scientific research. America and Europe, however, seem to be in a bizarre parallel contest: which can make its scientists’ lives more difficult by imposing the most muddled Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Biotechnology Patenting in Europe Event

2390666040_2e6b0a9a78_m

BIO hosted a Biotechnology Patenting in Europe event last week here at BIO’s offices where attorneys from Carpmaels and Ransford addressed various issues of interest to U.S. biotechnology companies. Huw Halleybone discussed the relative challenges of patent harmonization in Europe quoting some reports that indicate that the cost of a European patent is 10 times the amount of the United States.  Most of this cost is mainly due to language translation requirements and renewal fees.  Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

The Truth About Biotech Crops

There have been some misconceptions floating around in the internet with regard to biotech crop opposition in Europe and Japan. To set the record straight, neither Europe nor Japan is opposed to biotech crops. Their approval processes may take longer than those in the United States, Canada, Australia, and many other countries, but Japan and many European countries are importing biotech food and feed products, and several European countries successfully grow biotech crops. This technology Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , ,